You just read:

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer

News provided by

Innovent Biologics, Inc.

Jan 01, 2019, 19:00 ET